subject area of
- A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS) Journal Articles
- A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age Journal Articles
- Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants Journal Articles
- Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants Journal Articles
- Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons Journal Articles
- Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies Journal Articles
- Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015) Journal Articles
- Comparison of Viral Isolation and Multiplex Real-Time Reverse Transcription-PCR for Confirmation of Respiratory Syncytial Virus and Influenza Virus Detection by Antigen Immunoassays Journal Articles
- Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada Journal Articles
- First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015) Journal Articles
- Global molecular diversity of RSV – the “INFORM RSV” study Journal Articles
- Interactions of viral pathogens on hospital admissions for pneumonia, croup and chronic obstructive pulmonary diseases: results of a multivariate time-series analysis Journal Articles
- Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection Journal Articles
- Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data Journal Articles
- Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy Journal Articles
- Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Journal Articles
- Predictors of Poor Outcomes Among Infants With Respiratory Syncytial Virus–associated Acute Lower Respiratory Infection in Botswana Journal Articles
- Prioritising respiratory syncytial virus prevention in low-income and middle-income countries Journal Articles
- Re: “Completed Weeks of Gestation and Risk of Respiratory Syncytial Virus in Late Preterm Infants” Journal Articles
- Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada Journal Articles
- Respiratory Syncytial Virus Preterm (32–36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017 Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab Journal Articles
- Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations Journal Articles
- Respiratory syncytial virus (RSV) infection in children with medical complexity Journal Articles
- Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016) Journal Articles
- Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants Journal Articles
- Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada Journal Articles
- The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus Journal Articles
- Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada Journal Articles